Mitochondrial-targeted nano-enhancer driving a self-amplifying NAD<sup>+</sup> feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration.
A mitochondria-targeted nano-enhancer can shift MSC metabolism to improve bone regeneration in rats, but human applicability is uncertain.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpusSummary and findings
The study developed a mitochondria-targeted nano-enhancer to modulate energy metabolism in mesenchymal stem cell (MSC) spheroids for bone regeneration. The nano-enhancer shifts MSC metabolism from glycolysis to oxidative phosphorylation, enhancing osteogenic capacity in vitro and bone regeneration in a rat model. The approach involves a self-amplifying NAD+ feedback loop activated by a PQQ cofactor.
Abstract
Mitochondrial oxidative phosphorylation (OXPHOS) plays a crucial role in determining the functional fate of mesenchymal stem cells (MSCs). However, effective strategies to precisely modulate mitochondrial bioenergetics within three-dimensional (3D) MSC spheroids to improve bone repair remain limited. In this study, we have developed a mitochondria-targeted nano-enhancer (BP@PDA-TPP/Q) to enhance the therapeutic potential of MSC spheroids by reprogramming their energy metabolism for bone regeneration. The BP@PDA-TPP/Q nano-enhancer was constructed with black phosphorus (BP) nanosheets as a biodegradable core and polydopamine (PDA) as a stabilizing coating for ligand conjugation and PQQ loading; triphenylphosphonium (TPP) directed the nanocarrier to mitochondria, where the delivered pyrroloquinoline quinone (PQQ) served as an intramitochondrial redox cofactor to drive a self-amplifying NAD<sup>+</sup> feedback loop. Within this cascade, the localized PQQ cofactor activates the SIRT3/PGC-1α axis to upregulate nicotinamide phosphoribosyltransferase (NAMPT) and the mitochondrial transporter SLC25A51, which cooperatively accelerate NAD<sup>+</sup> salvage biosynthesis and mitochondrial import, thereby continuously sustaining and expanding the intramitochondrial NAD<sup>+</sup> pool. Consequently, the metabolic preference of MSC spheroids shifts from glycolysis toward OXPHOS. This metabolic reprogramming significantly improves the osteogenic capacity of spheroids in vitro and leads to substantial bone regeneration in a rat calvarial defect model. Our study introduces a novel nano-therapeutic approach for bone regeneration and broadens the conceptual foundation for advancing stem cell therapy through targeted metabolic regulation.
Background
Mitochondrial oxidative phosphorylation is crucial for the functional fate of mesenchymal stem cells, but strategies to modulate this process for bone repair are limited. This study addresses the need for effective modulation of mitochondrial bioenergetics in 3D MSC spheroids. The research aims to enhance bone regeneration by reprogramming MSC energy metabolism.
Methods
The study utilized a mitochondria-targeted nano-enhancer constructed with black phosphorus nanosheets and polydopamine coating for ligand conjugation and PQQ loading. The nano-enhancer was directed to mitochondria using triphenylphosphonium, where PQQ activated a self-amplifying NAD+ feedback loop. The primary outcomes were the shift in metabolic preference of MSC spheroids and bone regeneration in a rat calvarial defect model.
Results
The nano-enhancer successfully shifted the metabolic preference of MSC spheroids from glycolysis to oxidative phosphorylation. This metabolic reprogramming significantly improved the osteogenic capacity of spheroids in vitro. In a rat calvarial defect model, substantial bone regeneration was observed, indicating the potential of this approach for bone repair.
Interpretation
The findings suggest that targeting mitochondrial bioenergetics can enhance the osteogenic potential of MSCs. While the results are promising, they are based on in vitro and animal models, which may not fully predict human outcomes. The effect size in terms of bone regeneration is substantial in the rat model, but clinical significance in humans remains to be determined.
Key findings
- Mitochondria-targeted nano-enhancer shifts MSC metabolism to OXPHOS.
- Enhanced osteogenic capacity of MSC spheroids in vitro.
- Substantial bone regeneration observed in rat calvarial defect model.
Limitations
- Rat model only, no human data
- In vitro findings may not translate to clinical outcomes
- Potential species-specific metabolic differences